News
SER
1.200
-11.11%
-0.150
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Serina Therapeutics (SER)
TipRanks · 3d ago
Weekly Report: what happened at SER last week (1109-1113)?
Weekly Report · 3d ago
Serina Therapeutics GAAP EPS of -$0.31 beats by $0.03, revenue of $0.13M
Seeking Alpha · 6d ago
Weekly Report: what happened at SER last week (1102-1106)?
Weekly Report · 11/09 09:27
Weekly Report: what happened at SER last week (1026-1030)?
Weekly Report · 11/02 09:27
BTIG Reaffirms Their Buy Rating on Serina Therapeutics (SER)
TipRanks · 10/27 00:37
Serina Therapeutics Price Target Maintained With a $8.00/Share by BTIG
Dow Jones · 10/26 10:01
BTIG Reiterates Buy on Serina Therapeutics, Maintains $8 Price Target
Benzinga · 10/26 09:51
Weekly Report: what happened at SER last week (1019-1023)?
Weekly Report · 10/26 09:26
Weekly Report: what happened at SER last week (1012-1016)?
Weekly Report · 10/19 09:27
Serina Therapeutics management to meet virtually with BTIG
TipRanks · 10/14 18:25
Weekly Report: what happened at SER last week (1005-1009)?
Weekly Report · 10/12 09:28
Serina Therapeutics Streamlines Capital Structure After Preferred Elimination
TipRanks · 10/09 21:50
Serina Therapeutics management to meet virtually with BTIG
TipRanks · 10/09 18:30
Weekly Report: what happened at SER last week (0928-1002)?
Weekly Report · 10/05 09:28
Weekly Report: what happened at SER last week (0921-0925)?
Weekly Report · 09/28 09:27
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Barchart · 09/23 15:18
Weekly Report: what happened at SER last week (0914-0918)?
Weekly Report · 09/21 09:27
Weekly Report: what happened at SER last week (0907-0911)?
Weekly Report · 09/14 09:28
Serina Therapeutics: Early SER-252 Efficacy Signal and Strategic Positioning Support Unchanged $8 Price Target and Buy Rating
TipRanks · 09/11 09:55
More
Webull provides a variety of real-time SER stock news. You can receive the latest news about Serina Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.